While biopharma's blue chip companies continue to post strong gains, companies working on bringing new therapeutics to the marketplace have had a tougher time to garner excitement from investors with the BioWorld Drug Developers index recording a 2.1 percent fall in value in July. The downward trajectory has continued into this month and at market close last Thursday the index had fallen a further 4.1 percent. In comparison the Nasdaq Composite index fell just 2 percent and the Dow Jones Industrial Average was down marginally at 0.6 percent.